Traws Pharma, Inc. - Common Stock TRAW 深 滬
等待開盤 12-12 09:30:00 美东时间
2.33
-0.140
-5.67%
華盛通- 最 高2.56
- 今 開2.46
- 成交量 12.96万股
- 最 低 2.2835
- 昨 收 2.47
- 總市值 1645.87万
- 52周最高 19.44
- 市盈率 靜 --
- 換手率 1.83%
- 52周最低 0.97
- 委 比 -71.64%
- 總股本 706.38万
- 歷史最高 1751062.50
- 量 比 0.71
- 振 幅 11.19%
- 歷史最低 0.97
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
HC Wainwright & Co. Initiates Coverage On Traws Pharma with Buy Rating, Announces Price Target of $8
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Traws Pharma (NASDAQ:TRAW) with a Buy rating and announces Price Target of $8.
12-03 20:00
Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical stud...
10-28 00:59
Traws Pharma Approves Executive Stock Options Grant
Traws Pharma ( ($TRAW) ) has provided an update. On October 12, 2025, Traws Pha...
10-18 05:28
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma, Inc. has appointed John Leaman, MD, as an independent director, effective October 1, 2025. The company also removed the interim titles of its executives, Iain Dukes and Charles Parker, who are now CEO and CFO, respectively. Dr. Leaman brings extensive experience in finance and corporate strategy. The company is advancing ratutrelvir, a COVID-19 treatment, and tivoxavir marboxil, a potential bird flu and seasonal influenza therapy, w...
10-06 11:00
Annovis Bio appoints CFO
Clinical drug platform company Annovis Bio (NYSE:ANVS) announced on Thursday the appointment of Mark Guerin as CFO. Guerin has previously served at Onconova Therapeutics (TRAW), now known as Traws Pha...
09-25 19:55
Traws Pharma Receives HREC Approval To Initiate Phase 2 COVID Studies Of Ratutrelvir, A Ritonavir-Free Treatment, With Results Expected By Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVIDSeparate single-arm trial
08-18 19:08
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma announced the launch of Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, to compare its safety and efficacy with Paxlovid. The trials will assess disease rebound rates, Long COVID incidence, and safety in Paxlovid-ineligible patients. Top-line results are expected by year-end 2025. Ratutrelvir aims to overcome shortcomings of current treatments, including unfavorable drug interactions and limited efficacy, with once-...
08-18 11:00
Traws Pharma Q2 2025 GAAP EPS $(0.11) Up From $(20.52) YoY, Sales $2.733M Up From $57.000K YoY
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20.52) per share from the same period last year. The company reported $2.733 million in sales
08-14 19:04
